{"id":"gsk-biologicals-ipv-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain, redness, or swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability or fussiness"},{"rate":null,"effect":"Drowsiness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Inactivated poliovirus vaccine (IPV) contains chemically inactivated (killed) poliovirus particles that trigger humoral and cellular immune responses without causing disease. The vaccine induces production of neutralizing antibodies against all three poliovirus serotypes, preventing infection and transmission of wild-type poliovirus.","oneSentence":"IPV vaccine stimulates the immune system to produce antibodies against inactivated poliovirus types 1, 2, and 3, providing protection against poliomyelitis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:44.963Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Poliomyelitis prevention in infants and children"}]},"trialDetails":[{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT06333275","phase":"","title":"Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-14","conditions":"Vaccine Immunity in CAR-T Cell Therapy Recipients","enrollment":80},{"nctId":"NCT01568060","phase":"","title":"Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-05-21","conditions":"Acellular Pertussis, Diphtheria, Tetanus","enrollment":645},{"nctId":"NCT01144663","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Infections, Meningococcal, Meningococcal Vaccines","enrollment":2095},{"nctId":"NCT03207750","phase":"PHASE3","title":"This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Rotavirus Infection, Rotavirus Vaccines","enrollment":1280},{"nctId":"NCT02173704","phase":"PHASE3","title":"Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-11","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":225},{"nctId":"NCT01453998","phase":"PHASE2","title":"Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-10-14","conditions":"Acellular Pertussis, Hepatitis B, Haemophilus Influenzae Type b","enrollment":657},{"nctId":"NCT00454987","phase":"PHASE4","title":"Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05-16","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis, Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine","enrollment":288},{"nctId":"NCT00148941","phase":"PHASE3","title":"Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-01-06","conditions":"Tetanus, Acellular Pertussis, Diphtheria","enrollment":4209},{"nctId":"NCT01021293","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-28","conditions":"Poliomyelitis, Poliomyelitis Vaccines","enrollment":1101},{"nctId":"NCT01171989","phase":"PHASE2","title":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-18","conditions":"Tetanus, Diphtheria, Haemophilus Influenzae Type b","enrollment":391},{"nctId":"NCT01577732","phase":"PHASE3","title":"Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-08","conditions":"Acellular Pertussis, Haemophilus Influenzae Type b, Tetanus","enrollment":321},{"nctId":"NCT00609492","phase":"PHASE3","title":"Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01-03","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae Vaccines","enrollment":245},{"nctId":"NCT00463437","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-25","conditions":"Hepatitis B, Acellular Pertussis, Tetanus","enrollment":1437},{"nctId":"NCT00325156","phase":"PHASE4","title":"Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11-02","conditions":"Diphtheria, Tetanus, Poliomyelitis","enrollment":2590},{"nctId":"NCT01353703","phase":"PHASE3","title":"Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04-16","conditions":"Poliomyelitis, Tetanus, Acellular Pertussis","enrollment":224},{"nctId":"NCT01153841","phase":"PHASE3","title":"Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-17","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae Vaccines","enrollment":300},{"nctId":"NCT01309646","phase":"PHASE3","title":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-04","conditions":"Poliomyelitis, Tetanus, Acellular Pertussis","enrollment":454},{"nctId":"NCT00753649","phase":"PHASE4","title":"Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09-23","conditions":"Hepatitis B, Tetanus, Poliomyelitis","enrollment":224},{"nctId":"NCT02907216","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-16","conditions":"Rotavirus","enrollment":292},{"nctId":"NCT02858440","phase":"PHASE3","title":"A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-13","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":235},{"nctId":"NCT01340898","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-27","conditions":"Meningococcal Infection","enrollment":753},{"nctId":"NCT00466947","phase":"PHASE3","title":"COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-28","conditions":"Infections, Streptococcal","enrollment":23802},{"nctId":"NCT00652951","phase":"PHASE3","title":"Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04-01","conditions":"Infections, Streptococcal","enrollment":780},{"nctId":"NCT00370396","phase":"PHASE3","title":"Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-25","conditions":"Infections, Streptococcal","enrollment":1200},{"nctId":"NCT01204658","phase":"PHASE2","title":"Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-27","conditions":"Infections, Streptococcal","enrollment":576},{"nctId":"NCT01235949","phase":"PHASE4","title":"Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-11-12","conditions":"Infections, Streptococcal","enrollment":850},{"nctId":"NCT01094171","phase":"PHASE4","title":"Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-03","conditions":"Poliomyelitis","enrollment":400},{"nctId":"NCT01003418","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-11-17","conditions":"Influenza","enrollment":8},{"nctId":"NCT01323647","phase":"PHASE3","title":"Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-25","conditions":"Poliomyelitis","enrollment":957},{"nctId":"NCT00875641","phase":"","title":"Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04-20","conditions":"Infections, Rotavirus","enrollment":390659},{"nctId":"NCT00345358","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-18","conditions":"Infections, Streptococcal","enrollment":600},{"nctId":"NCT00547248","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-22","conditions":"Infections, Streptococcal","enrollment":756},{"nctId":"NCT00513409","phase":"PHASE2","title":"Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-22","conditions":"Infections, Streptococcal","enrollment":163},{"nctId":"NCT00937404","phase":"PHASE1","title":"Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-04","conditions":"Poliomyelitis","enrollment":25},{"nctId":"NCT00390910","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-01","conditions":"Infections, Streptococcal","enrollment":286},{"nctId":"NCT00344318","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-07","conditions":"Infections, Streptococcal","enrollment":806},{"nctId":"NCT00290342","phase":"PHASE3","title":"Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-01","conditions":"Tetanus, Acellular Pertussis, Diphtheria","enrollment":458},{"nctId":"NCT02002156","phase":"PHASE4","title":"A Study of the Interaction Between BCG And MenC Immunisation: BAM","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-06-20","conditions":"BCG Infection, Reaction - Vaccine, Immune Response","enrollment":28},{"nctId":"NCT01119625","phase":"PHASE3","title":"Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-12","conditions":"Infections, Streptococcal","enrollment":238},{"nctId":"NCT00127855","phase":"PHASE2","title":"Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":409},{"nctId":"NCT00586612","phase":"PHASE3","title":"Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-12-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":313},{"nctId":"NCT00129116","phase":"PHASE2","title":"3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":388},{"nctId":"NCT01248884","phase":"PHASE2","title":"Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-09","conditions":"Tetanus, Poliomyelitis, Hepatitis B","enrollment":721},{"nctId":"NCT01245049","phase":"PHASE3","title":"Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-01","conditions":"Acellular Pertussis, Poliomyelitis, Tetanus","enrollment":387},{"nctId":"NCT00426361","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-13","conditions":"Infections, Papillomavirus","enrollment":751},{"nctId":"NCT00307034","phase":"PHASE3","title":"Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-01","conditions":"Infections, Streptococcal","enrollment":351},{"nctId":"NCT00196976","phase":"PHASE2","title":"Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-24","conditions":"Infections, Meningococcal","enrollment":461},{"nctId":"NCT01323959","phase":"PHASE4","title":"Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-01","conditions":"Acellular Pertussis, Poliomyelitis, Diphtheria","enrollment":212},{"nctId":"NCT00871338","phase":"PHASE2","title":"Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-24","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":284},{"nctId":"NCT00871000","phase":"PHASE3","title":"Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04-01","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":303},{"nctId":"NCT00611559","phase":"PHASE4","title":"Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-14","conditions":"Poliomyelitis, Acellular Pertussis, Tetanus","enrollment":283},{"nctId":"NCT00627458","phase":"PHASE2","title":"Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-01","conditions":"Acellular Pertussis, Diphtheria, Poliomyelitis","enrollment":403},{"nctId":"NCT01086423","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03-01","conditions":"Tetanus, Poliomyelitis, Acellular Pertussis","enrollment":985},{"nctId":"NCT00964028","phase":"PHASE3","title":"Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-12-01","conditions":"Haemophilus Influenzae Type b, Acellular Pertussis, Diphtheria","enrollment":50},{"nctId":"NCT01449812","phase":"PHASE3","title":"Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-10-01","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":831},{"nctId":"NCT00891176","phase":"PHASE3","title":"Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-14","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":582},{"nctId":"NCT00920439","phase":"PHASE3","title":"Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-01","conditions":"Poliomyelitis","enrollment":26},{"nctId":"NCT03128489","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2017-12-01","conditions":"Diphtheria, Acellular Pertussis, Haemophilus Influenzae Type b","enrollment":""},{"nctId":"NCT00289796","phase":"PHASE2","title":"Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-07","conditions":"Hepatitis B","enrollment":121},{"nctId":"NCT00376779","phase":"PHASE2","title":"Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":450},{"nctId":"NCT00322335","phase":"PHASE3","title":"Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":230},{"nctId":"NCT00320463","phase":"PHASE3","title":"Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04","conditions":"Diphtheria, Hepatitis B, Poliomyelitis","enrollment":415},{"nctId":"NCT00356564","phase":"PHASE4","title":"Persistence of the Immune Response to Hepatitis B in 7-9 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-07","conditions":"Hepatitis B","enrollment":350},{"nctId":"NCT00335881","phase":"PHASE4","title":"Persistence of the Immune Response to Hepatitis B in 4-6 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06","conditions":"Hepatitis B","enrollment":300},{"nctId":"NCT00316147","phase":"PHASE3","title":"Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-12","conditions":"Diphtheria, Acellular Pertussis, Tetanus","enrollment":224},{"nctId":"NCT00338351","phase":"PHASE2","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04","conditions":"Hepatitis A","enrollment":240},{"nctId":"NCT00258700","phase":"PHASE3","title":"Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-02","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":478},{"nctId":"NCT00729001","phase":"PHASE2","title":"Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-11","conditions":"Infections, Rotavirus","enrollment":529},{"nctId":"NCT01294605","phase":"PHASE4","title":"Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-04","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":460},{"nctId":"NCT00263692","phase":"PHASE2","title":"Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-11","conditions":"Diphtheria, Acellular Pertussis, Tetanus","enrollment":401},{"nctId":"NCT00346892","phase":"PHASE2","title":"To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-11","conditions":"Rotavirus Infections","enrollment":450},{"nctId":"NCT00879827","phase":"PHASE3","title":"Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-09","conditions":"Diphtheria, Poliomyelitis, Hepatitis B","enrollment":60},{"nctId":"NCT01277705","phase":"PHASE3","title":"Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-01","conditions":"Tetanus, Diphtheria, Acellular Pertussis","enrollment":806},{"nctId":"NCT01457547","phase":"PHASE4","title":"Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10","conditions":"Hepatitis B, Poliomyelitis, Diphtheria","enrollment":494},{"nctId":"NCT02447978","phase":"","title":"Duration of Protection: GSK DTaP Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-02","conditions":"Diphtheria, Acellular Pertussis, Tetanus","enrollment":1},{"nctId":"NCT01831050","phase":"PHASE4","title":"Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2013-05","conditions":"Poliomyelitis","enrollment":1420},{"nctId":"NCT01810731","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya","status":"WITHDRAWN","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-04","conditions":"Influenza, Human, HIV, Malaria","enrollment":""},{"nctId":"NCT01651247","phase":"","title":"Assessment of the Serologic Response to Porcine Circovirus Type 1 (PCV-1) in the Serum of Infants and Toddlers, Following Administration of IPV (Inactivated Poliovirus Vaccine)-Containing Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05","conditions":"Presence of Materials From PCV-1","enrollment":1},{"nctId":"NCT00514033","phase":"","title":"A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07","conditions":"Poliomyelitis","enrollment":349},{"nctId":"NCT00133445","phase":"PHASE2","title":"Pentavalent DTaP-Hep B-IPV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-12","conditions":"Diphtheria, Hepatitis B, Poliomyelitis","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GSK Biologicals' IPV vaccine","genericName":"GSK Biologicals' IPV vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"IPV vaccine stimulates the immune system to produce antibodies against inactivated poliovirus types 1, 2, and 3, providing protection against poliomyelitis. Used for Poliomyelitis prevention in infants and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}